CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
lurbinectedin (PM01183)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02451007
NCT02451007Phase 2Completed
CompareCT.gov

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors

PharmaMar·interventional·Posted May 21, 2015·Updated Nov 19, 2019

In Brief

A Phase 2 clinical trial evaluating lurbinectedin (PM01183) for Solid Tumors. Completed, enrolled 39 participants across 16 sites in 2 countries.

Detailed Summary

Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in patients with selected solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesSpain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 21, 2015
Enrollment StartAug 12, 2015
Primary CompletionAug 19, 2016
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 11.1 years ago

Interventions

lurbinectedin (PM01183)drug